1227 related articles for article (PubMed ID: 20170205)
21. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
23. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
24. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
25. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.
Vavić N; Rančić N; Cikota-Aleksić B; Magić Z; Cimeša J; Obrenčević K; Radojević M; Mikov M; Dragojević-Simić V
Vojnosanit Pregl; 2016 Jul; 73(7):663-7. PubMed ID: 29314799
[TBL] [Abstract][Full Text] [Related]
26. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
29. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
30. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
31. Beyond Single Nucleotide Polymorphisms:
Brazeau DA; Attwood K; Meaney CJ; Wilding GE; Consiglio JD; Chang SS; Gundroo A; Venuto RC; Cooper L; Tornatore KM
Front Genet; 2020; 11():889. PubMed ID: 32849848
[TBL] [Abstract][Full Text] [Related]
32. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
[TBL] [Abstract][Full Text] [Related]
33. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
34. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
35. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
[TBL] [Abstract][Full Text] [Related]
36. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
37. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
38. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
39. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients.
Zhang Y; Li JL; Fu Q; Wang XD; Liu LS; Wang CX; Xie W; Chen ZJ; Shu WY; Huang M
Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472
[TBL] [Abstract][Full Text] [Related]
40. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
